The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Alliance A061202: POM-DEX vs IXA-POM-DEX in R/R multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, reports the findings of Alliance A061202 (NCT02004275), a Phase I/II study comparing the safety and efficacy of pomalidomide, dexamethasone and ixazomib (IXA-POM-DEX) versus pomalidomide and dexamethasone (POM-DEX) in lenalidomide-refractory patients with multiple myeloma. Dr Richardson first outlines the study design and explains that patients treated with the IXA-POM-DEX triplet had a significantly higher progression-free survival (PFS). In addition, Dr Richardson explains that this all-oral combination was well-tolerated and there was no COVID-19-related mortality. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
